Project Aim(s): This proposal aims to combine our novel EEG based technology with detailed neuropsychological assessment to provide a quantitative measure of cognitive change in MS that could be used in a clinical trial setting. The study will also provide an opportunity to assess for the first time the impact of Cladribine on cognitive performance using conventional screening tools, detailed neuropsychological batteries, and experimental neurophysiology based paradigms that could be harnessed for future nested case control studies.
Research
DRNI Members Research is a list of ongoing and completed research carried out by DRNI members.
You can search via project type, disease, or Principal Investigator/Researcher name.
Search
Research type
Disease area
Field of research
Project Aim(s): The aim is to use epidemiologic and clinical datasets to track in detail the patient journey in ALS, and from this to provide a robust staging system, generate cost models and appropriate health economic metrics, and to inform the design of a user-friendly electronic care matrix for optimal ALS management that can be used by non-specialists, and that in turn can be modified for use in other neurodegenerative conditions.
Project Aim(s): This project aims to develop and evaluate group-based psychological interventions for caregivers of patients with ALS, where the objective is to reduce anxiety, low mood, and caregiver burden. The overall purpose of this study is to evaluate the effectiveness and efficacy of psychological interventions with this group; to inform best practice regarding the identification and management of caregiver burden in ALS; and to create a formal psychological intervention tailored specifically to the needs and wants of ALS caregivers.
Project Aim(s): To develop and promote resilience in family carers of people with dementia.
Project Aim(s): Our overall aim is to revise existing phenotypic classifications using pathways and network analyses to generate newer more biologically classifications based on causative mechanisms, potential new therapeutic drug targets and indications, treatment response profiles and clinical sub-phenotypes.
Alzheimer’s and Parkinson’s diseases (AD and PD) are the two most common neurodegenerative conditions. They cause major costs for society and suffering and death for millions of patients around the globe. In Europe, more than 8 million individuals have AD or PD. Current treatments are symptomatic but do not stop the underlying disease process. Using biomarkers, we can detect biochemical changes that show when neurons start to die. There are also biochemical tests for brain changes that are specific to AD and PD.
Deciphering ALS Heterogeneity: A Precision Medicine Approach to Network-based Biomarker Development.
Project Aim(s):
(i) To continue to characterise the clinical subphenotypes of ALS and to further elucidate the observed clinical and genetic overlap between ALS and neuropsychiatric disorders by detailed study of endophenotypes in first and second degree relatives.
(ii) To identify heterogeneous disease subcohorts based on genomic signatures, including those that overlap between ALS and neuropsychiatric illness.
Project Aim(s):
(i) Using existing data, to characterize the impact of ALS stage, cognitive and behavioural effects in ALS on caregiver burden, and to ascertain the unmet psychological and psychosocial needs of caregivers.
(ii) To provide new data focussing on subjective and objective aspects of caregiver burden that can inform psychologically tailored interventions that enable self-management of carer burden.
Project Aim(s): To explore the attitudes of Irish and Swedish General Practitioners (GPs) to the diagnosis and disclosure of dementia to patients; to investigate GP under-graduate/post-graduate training in dementia; to examine the post-diagnostic support services available to GPs in both countries and to investigate the extent to which dementia is perceived as stigmatising.
To determine the evidence for diet modification - Specifically, thickening fluids to prevent aspiration in people with dementia and swallowing difficulties.